Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
NCC Launches Investigator-Led Studies on 5 Unapproved, Off-Label Drugs for Pediatric, AYA Cancers
The National Cancer Center (NCC) said on January 19 that it has kicked off investigator-initiated studies earlier this month for six unapproved or off-label medicines including five from Novartis, targeting pediatric and AYA (adolescent and young adult) cancers. The studies…
To read the full story
Related Article
- NCC to Add Cabozantinib, Valemetostat to Pediatric, AYA Cancer Trial
February 27, 2024
ACADEMIA
- Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
- Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
- NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
- Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
- Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…